Has Johnny Dy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,161,369 in general payments to Johnny Dy, MD across 741 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Johnny Dy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Johnny Dy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Johnny Dy, MD

Cardiovascular Disease · Lenoir, NCNPI 1528021664

Payments from drug & device makers

$2,161,369in general payments, 2019–2025

Across 741 payments — averaging $2916.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1.9M
Janssen Research & Development, LLC$119K
Eli Lilly$34K
Boehringer Ingelheim International GmbH$31K
Boehringer Ingelheim$28K
Merck$20K
plus $71K from 37 others

$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$500

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	74	$1,857,370
Janssen Research & Development, LLC	28	$119,010
Eli Lilly	3	$34,354
Boehringer Ingelheim International GmbH	58	$31,279
Boehringer Ingelheim	38	$28,000
Merck	12	$19,949
Boehringer Ingelheim Pharma GmbH & Co.kg	4	$16,692
Ionis Pharmaceuticals, Inc.	17	$14,450
E.r. Squibb & Sons, L.L.C.	23	$11,045
Pfizer	47	$10,713
AstraZeneca	30	$7,871
Medtronic(2 entities)	56	$3,728
Johnson & Johnson	111	$1,680
Amgen	59	$1,068
Abbott	25	$703
Boston Scientific	22	$596
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	35	$575
Novo Nordisk	23	$351
Bayer	17	$308
Actelion Pharmaceuticals US, Inc.	3	$250
Amarin Pharma, Inc.	12	$209
Acist Medical Systems, Inc.	4	$185
Preventric Diagnostics, Inc.	1	$118
Vital Connect, Inc	4	$103
Abiomed	1	$103
Esperion Therapeutics, Inc.	5	$97
Sanofi-aventis U.S. LLC	5	$92
Kiniksa Pharmaceuticals International, PLC	4	$78
Cardinal Health 200 LLC	2	$50
Shockwave Medical, Inc	1	$42
Irhythm Technologies, Inc.	3	$40
GSK	2	$39
Scpharmaceuticals Inc.	2	$36
Bard Peripheral Vascular, Inc.	1	$31
Impulse Dynamics (USA) Inc.	1	$23
Lilly USA, LLC	1	$20
Lexicon Pharmaceuticals, Inc.	1	$19
Cook Medical LLC	1	$16
Kowa Pharmaceuticals America, Inc.	1	$16
Inspire Medical Systems, Inc.	1	$16
Biotronik Inc.	1	$16
Philips North America LLC	1	$15
Regeneron Healthcare Solutions, Inc.	1	$13

How this compares

$2,161,369 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina →

Medicare billing

Part B allowed, 2024

$742,657

Medicare patients

689

Services billed

10,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Lenoir

John AlexanderDurham$76.8M
Christopher GrangerDurham$24.7M
Jonathan PicciniDurham$14.3M
Adrian HernandezDurham$13.2M
Gary FelkerDurham$12.7M
Robert MentzDurham$6M
Michael ShapiroWinston-Salem$5.4M
Kirkwood AdamsChapel Hill$4.9M
Matthew JanikWilmington$4M
Nishant ShahDurham$3.5M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →